Moleculin Abstract Accepted for 2024 EHA Hybrid Congress Poster Presentation

May 16, 2024 -- Moleculin Biotech, Inc, (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company dedicated to discovering treatments for difficult-to-treat tumors and viruses, has announced that its abstract has been approved for a poster presentation at the upcoming EHA2024 Hybrid Congress. This event will take place from June 13-16, 2024, in Madrid, Spain, and will also be accessible virtually.

The details of the poster presentation are as follows:
- Abstract: P537
- Session: Acute Myeloid Leukemia – Clinical
- Title: LIPOSOMAL ANNAMYCIN (L-ANN) IN COMBINATION WITH CYTARABINE FOR TREATMENT OF PATIENTS WITH ACUTE MYELOID LEUKAEMIA (AML) REFRACTORY TO OR RELAPSED (R/R) AFTER INDUCTION THERAPY (MB-106 STUDY)
- Presenting Author: Wolfram C. M. Dempke, MD, PhD, MBA, European Chief Medical Officer of Moleculin

Moleculin Biotech, Inc. is advancing its clinical-stage pharmaceutical endeavors through a diverse pipeline aimed at treating challenging tumors and viruses. The Company's primary program, Annamycin, is a next-generation anthracycline that circumvents multidrug resistance mechanisms and mitigates the cardiotoxic effects typically associated with current anthracyclines. Annamycin is under development for treating relapsed or refractory acute myeloid leukemia (AML) and lung metastases in soft tissue sarcoma (STS).

The Company's portfolio also includes WP1066, which acts as an Immune/Transcription Modulator. This drug has the potential to inhibit p-STAT3 and other oncogenic transcription factors while enhancing a natural immune response. WP1066 is being targeted for brain tumors, pancreatic cancer, and other malignancies. Additionally, Moleculin is working on WP1220, an analog of WP1066, designed for the topical treatment of cutaneous T-cell lymphoma.

Further, Moleculin is investing in the development of antimetabolites like WP1122. This agent holds promise for treating viruses and various cancer types, including brain tumors and pancreatic cancer.

Overall, Moleculin Biotech, Inc. is steadfast in its mission to develop innovative solutions for treating some of the most challenging diseases, leveraging their deep expertise in pharmaceuticals and clinical research.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!